(Press-News.org) PHILADELPHIA - A new clinical trial will soon begin testing whether early medical intervention in people at risk for Alzheimer's can slow down progression of disease pathology before symptoms emerge, as outlined in Science Translational Medicine. For the first time, people with no Alzheimer's disease symptoms will be told of their risk status before being asked to join the randomized controlled trial. As part of the overall prevention trial, Penn Medicine neurodegenerative ethics experts will monitor how learning about their risk of developing Alzheimer's impacts trial participants.
Alzheimer's disease afflicts more than 13 percent of individuals over the age of 65, and remains one of the most feared consequences of aging.
"In order to ethically conduct a study where patients will learn they have a greater chance of developing Alzheimer's disease dementia, we've integrated continual assessments of potential participants throughout the process, to ensure that they are ready to receive information about their amyloid status and aren't having any adverse reactions after finding out," said Jason Karlawish, MD, professor of Medicine and Medical Ethics and Health Policy in the Perelman School of Medicine at the University of Pennsylvania and Associate Director of the Penn Memory Center.
Dr. Karlawish directs the Penn Neurodegenerative Disease Ethics and Policy Program. "This study is an important step in determining the consequences of being tested for Alzheimer's disease before the person has disabling cognitive impairments."
The A4 trial requires that patients enrolled must have one of the pathologies typically seen in Alzheimer's disease dementia, which will be assessed using a brain PET scan that measures amyloid. Given that studies have shown that about one third of clinically normal older individuals have evidence of amyloid plaque accumulation but may not develop any cognitive symptoms within their lifetime, the patients who are enrolled in the trial based on positive amyloid results may or may not go on to develop Alzheimer's disease dementia.
"In addition to the study's primary aims - looking at whether early treatment can slow cognitive decline - we will carefully measure how disclosure impacts cognitive test performance, the perception of cognitive symptoms, quality of life and perceived risk of Alzheimer's in participants with and without evidence of amyloid accumulation," said Karlawish.
For more information on the new A4 trial (Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease), visit http://www.adcs.org/Studies/A4.aspx.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.
Alzheimer's prevention trial to monitor reactions to higher disease risk status
Penn neurodegenerative ethics expert to oversee ethical assessment within A4 prevention trial
ELSE PRESS RELEASES FROM THIS DATE:
NJIT physicist helps to discover a new structure in Earth's radiation belt
An NJIT physicist is a collaborator in the discovery of a new structure in Earth's inner radiation belt -- a zebra-striped structure of highly energized electrons that could endanger humans in space and also damage low-earth navigation and communication satellites. And surprisingly, the new structure is produced not by solar activity but by Earth's slow rotation. Scientists had previously thought Earth's rotation couldn't affect the motion of radiation belt particles. The data supporting these discoveries comes from a measuring device aboard the two NASA Van Allen Probes ...
Scientists describe gut bacteria that cause sepsis in preterm infants
Researchers studying intestinal bacteria in newborns have characterized the gut bacteria of premature infants who go on to develop sepsis, a serious and potentially life-threatening condition caused by bacteria in the bloodstream. Their findings suggest new strategies for the early detection and prevention of severe bloodstream infections. The research was funded by several components of the National Institutes of Health (NIH)—the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Human Genome Research Institute (NHGRI), ...
Ancient food webs developed modern structure soon after mass extinction
Researchers from the Santa Fe Institute and the Smithsonian Institution have pieced together a highly detailed picture of feeding relationships among 700 mammal, bird, reptile, fish, insect, and plant species from a 48 million year old lake and forest ecosystem. Their analysis of fossilized remains from the Messel deposit near Frankfurt, Germany, provides the most compelling evidence to date that ancient food webs were organized much like modern food webs. Their paper describing the research appears online and open access this week in Proceedings of the Royal Society ...
NIH grantees sharpen understanding of antibodies that may cut risk of HIV infection
What immune response should a vaccine elicit to prevent HIV infection? Two studies published online today bring scientists closer to answering this question by identifying previously unrecognized attributes of antibodies that appear to have reduced the risk of HIV infection in the only clinical trial to show efficacy, albeit modest, of an experimental vaccine regimen in people. Earlier analyses of the results of that trial, known as RV144, suggested that antibodies to sites within a part of the HIV envelope called V1V2 correlated with reduced risk of HIV infection. These ...
Patients enjoy good quality of life 10 years after esophagectomy and gastric pull-up
Beverly, MA, March 19, 2014 – Long-term survivors after esophagectomy with gastric pull-up can enjoy a satisfying meal and good quality of life according to a new study from a team of researchers at the University of Southern California Keck School of Medicine, Los Angeles. This study concluded that pessimism about the long-term quality of life after an esophagectomy on the part of treating physicians and patients is unwarranted. It is published in the Journal of Thoracic and Cardiovascular Surgery, an official publication of the American Association for Thoracic Surgery. ...
Texans are turning to a different kind of spirit -- vodka -- and saltier is better
DALLAS, March 19, 2014 — Texans, known for enjoying local beers and Dr Pepper soft drinks, now have a growing beverage industry that would appeal to James Bond, who is well-known for enjoying a good martini. Distillers are producing at least 17 Texas vodkas, researchers reported here today, and the most popular are, surprisingly, those that are a bit salty. Their report, "Shaken not stirred, y'all: A comparison of select Texas vodkas," covered the results of group tastings on the vodkas, as well as some surprising facts about the state's alcoholic beverage market. ...
The aging brain needs REST
Why do neurodegenerative diseases such as Alzheimer's affect only the elderly? Why do some people live to be over 100 with intact cognitive function while others develop dementia decades earlier? More than a century of research into the causes of dementia has focused on the clumps and tangles of abnormal proteins that appear in the brains of people with neurodegenerative diseases. However, scientists know that at least one piece of the puzzle has been missing because some people with these abnormal protein clumps show few or no signs of cognitive decline. A new study ...
Global warming may increase methane emissions from freshwater ecosystems
New research led by the University of Exeter suggests that rising global temperatures will increase the quantity of the key greenhouse gas methane emitted from freshwater ecosystems to the Earth's atmosphere – which could in turn lead to further warming. The collaborative study, led by Dr Gabriel Yvon-Durocher from the University of Exeter, collated data from hundreds of laboratory experiments and field surveys to demonstrate that the speed at which methane fluxes increase with temperature was the same whether single species populations of methanogens, microbial communities ...
Past HIV vaccine trials reveal new path to success
DURHAM, N.C. – A multi-national research team led by Duke Medicine scientists has identified a subclass of antibodies associated with an effective immune response to an HIV vaccine. The finding, reported in the March 19, 2014, issue of the journal Science Translational Medicine, helps explain why a combination of two vaccines was able to show some effect, when one vaccine alone did not. The study also provides key insights that could aid development of new vaccines. "More is not always better with an antibody response," said senior author Georgia D. Tomaras, Ph.D., ...
Radiotherapy after mastectomy benefits women with breast cancer in 1-3 lymph nodes
Glasgow, UK: Women whose breast cancer has spread to just a few lymph nodes under their arm are less likely to have their disease recur or to die from it if they have radiotherapy after mastectomy, according to new research to be presented at the European Breast Cancer Conference (EBCC-9) on Thursday and published in The Lancet today (Wednesday).  Dr Paul McGale will tell the meeting that, until now, there has been uncertainty over whether women with early breast cancer that has spread to just one, two or three lymph nodes under the arm gain any benefit from radiotherapy ...
LAST 30 PRESS RELEASES:
Scientists model 'true prevalence' of COVID-19 throughout pandemic
New breakthrough to help immune systems in the fight against cancer
Through the thin-film glass, researchers spot a new liquid phase
Administering opioids to pregnant mice alters behavior and gene expression in offspring
Brain's 'memory center' needed to recognize image sequences but not single sights
Safety of second dose of mRNA COVID-19 vaccines after first-dose allergic reactions
Changes in disparities in access to care, health after Medicare eligibility
Use of high-risk medications among lonely older adults
65+ and lonely? Don't talk to your doctor about another prescription
Exosome formulation developed to deliver antibodies for choroidal neovascularization therapy
Second COVID-19 mRNA vaccine dose found safe following allergic reactions to first dose
Plant root-associated bacteria preferentially colonize their native host-plant roots
Rare inherited variants in previously unsuspected genes may confer significant risk for autism
International experts call for a unified public health response to NAFLD and NASH epidemic
International collaboration of scientists rewrite the rulebook of flowering plant genetics
Improving air quality reduces dementia risk, multiple studies suggest
Misplaced trust: When trust in science fosters pseudoscience
Two types of blood pressure meds prevent heart events equally, but side effects differ
New statement provides path to include ethnicity, ancestry, race in genomic research
Among effective antihypertensive drugs, less popular choice is slightly safer
Juicy past of favorite Okinawan fruit revealed
Anticipate a resurgence of respiratory viruses in young children
Anxiety, depression, burnout rising as college students prepare to return to campus
Goal-setting and positive parent-child relationships reduce risk of youth vaping
New research identifies cancer types with little survival improvements in adolescents and young adul
Oncotarget: Replication-stress sensitivity in breast cancer cells
Oncotarget: TERT and its binding protein: overexpression of GABPA/B in gliomas
Development of a novel technology to check body temperature with smartphone camera
The mechanics of puncture finally explained
Extreme heat, dry summers main cause of tree death in Colorado's subalpine forests[Press-News.org] Alzheimer's prevention trial to monitor reactions to higher disease risk status
Penn neurodegenerative ethics expert to oversee ethical assessment within A4 prevention trial